Tag Archives: ALNY

Top 10 Biotech Stocks To Invest In 2019

Several analysts have recently updated their ratings and price targets for Concert Pharmaceuticals (NASDAQ: CNCE):

8/3/2018 – Concert Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. 8/2/2018 – Concert Pharmaceuticals had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $27.00 price target on the stock. They wrote, “We do not see earnings as the most meaningful indicator of value for a development-stage biotech. More importantly, Concert continues its steady progress on the clinical development front. A key catalyst is expected in 4Q18 with top-line readouts from the phase 2a trial of CTP-543 in alopecia areata at the 4 mg and 8 mg doses. A protocol amendment is also planned to evaluate the highest 12 mg dose. We anticipate data from the high-dose cohort will likely read out in 4Q19.”” 7/30/2018 – Concert Pharmaceuticals was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating. 7/24/2018 – Concert Pharmaceuticals was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating. 7/17/2018 – Concert Pharmaceuticals was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating. 6/26/2018 – Concert Pharmaceuticals was downgraded by analysts at ValuEngine from a “strong-buy” rating to a “buy” rating.

Concert Pharmaceuticals opened at $16.60 on Friday, Marketbeat Ratings reports. The stock has a market cap of $396.42 million, a price-to-earnings ratio of 4.07 and a beta of 1.03. Concert Pharmaceuticals Inc has a 52-week low of $13.57 and a 52-week high of $30.71.

Top 10 Biotech Stocks To Invest In 2019: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By Shane Hupp]

    ADAMCAPITAL Gestao de Recursos Ltda. lowered its holdings in Biogen Inc (NASDAQ:BIIB) by 30.5% in the 2nd quarter, HoldingsChannel reports. The fund owned 125,856 shares of the biotechnology company’s stock after selling 55,267 shares during the quarter. Biogen comprises approximately 1.8% of ADAMCAPITAL Gestao de Recursos Ltda.’s portfolio, making the stock its 16th largest holding. ADAMCAPITAL Gestao de Recursos Ltda.’s holdings in Biogen were worth $36,528,000 at the end of the most recent quarter.

  • [By Lee Jackson]

    This large-cap biotech will partner with Samsung Bioepis in the biosimilar world. Biogen Inc. (NASDAQ: BIIB) discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978, Biogen is one of the world’s oldest independent biotech companies, and patients worldwide benefit from its leading multiple sclerosis (MS) and innovative hemophilia therapies.

  • [By Todd Campbell]

    PTC Therapeutics (NASDAQ:PTCT) shares took off after updated data from a trial evaluating risdiplam suggested it could mount a stiff challenge to Biogen’s (NASDAQ:BIIB) and Ionis Pharmaceuticals’ (NASDAQ:IONS) Spinraza for the treatment of  spinal muscular atrophy (SMA), a rare and life-threatening genetic disease. The data is solid, but a one-and-done SMA treatment is already in late-stage studies at Novartis’ (NYSE:NVS), and that therapy could become available as soon as 2019. 

Top 10 Biotech Stocks To Invest In 2019: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Max Byerly]

    Wedbush Securities Inc. decreased its holdings in Amgen, Inc. (NASDAQ:AMGN) by 5.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 20,159 shares of the medical research company’s stock after selling 1,174 shares during the quarter. Wedbush Securities Inc.’s holdings in Amgen were worth $3,721,000 at the end of the most recent reporting period.

  • [By Max Byerly]

    Amgen (NASDAQ: AMGN) and aTyr Pharma (NASDAQ:LIFE) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, analyst recommendations and institutional ownership.

  • [By Keith Speights]

    It’s not too hard to find biotech stocks that are bargains right now. Two of the most attractively priced biotech stocks on the market are Amgen (NASDAQ:AMGN) and Gilead Sciences (NASDAQ:GILD). Both stocks also provide nice dividend yields for income-seeking investors.

  • [By Logan Wallace]

    Philadelphia Trust Co. decreased its holdings in Amgen, Inc. (NASDAQ:AMGN) by 8.0% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 74,676 shares of the medical research company’s stock after selling 6,501 shares during the quarter. Amgen makes up 1.2% of Philadelphia Trust Co.’s portfolio, making the stock its 22nd biggest position. Philadelphia Trust Co.’s holdings in Amgen were worth $13,784,000 as of its most recent SEC filing.

  • [By ]

    Amgen’s (NASDAQ:AMGN) past is filled with excitement. The company rose to become one of the biggest biotechs in the world. It grew a product lineup with multiple blockbuster drugs. Over the last decade, Amgen’s share price has more than tripled. But the excitement appears likely to diminish considerably for Amgen — at least for the next few years.

  • [By Cory Renauer]

    Lilly investors can also look forward to growing sales of the third new treatment for the prevention of migraine headaches. Emgality launched in October months after competing treatments from Amgen (NASDAQ:AMGN) and Teva Pharmaceuticals (NYSE:TEVA) late last year.

Top 10 Biotech Stocks To Invest In 2019: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Logan Wallace]

    BidaskClub upgraded shares of ArQule (NASDAQ:ARQL) from a hold rating to a buy rating in a report released on Saturday.

    A number of other research firms have also issued reports on ARQL. Roth Capital upped their price target on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Zacks Investment Research lowered ArQule from a buy rating to a hold rating in a research report on Wednesday, April 4th. ValuEngine upgraded ArQule from a hold rating to a buy rating in a research report on Wednesday, May 2nd. Finally, B. Riley set a $4.00 price target on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Seven analysts have rated the stock with a buy rating, The stock currently has an average rating of Buy and an average target price of $4.69.

  • [By Lisa Levin] Gainers
    Foot Locker, Inc. (NYSE: FL) rose 15.3 percent to $53.50 in pre-market trading after the company reported better-than-expected results for its first quarter.
    Evofem Biosciences, Inc. (NASDAQ: EVFM) rose 10.4 percent to $4.58 in pre-market trading. Evofem Biosciences reported closing of public offering of common stock and warrants.
    Resonant Inc. (NASDAQ: RESN) rose 7.3 percent to $4.88 in pre-market trading after declining 1.94 percent on Thursday.
    SolarEdge Technologies, Inc. (NASDAQ: SEDG) shares rose 5.7 percent to $59.65 in pre-market trading after falling 8.43 percent on Thursday.
    Yirendai Ltd. (NYSE: YRD) rose 5 percent to $30.00 in pre-market trading after reporting Q1 results.
    Deckers Outdoor Corp (NYSE: DECK) rose 4.9 percent to $108.75 in pre-market trading after reporteingd better-than-expected results for its fiscal fourth quarter.
    Blue Apron Holdings, Inc. (NYSE: APRN) rose 4.2 percent to $3.21 in pre-market trading after gaining 3.70 percent on Thursday.
    Recro Pharma, Inc. (NASDAQ: REPH) rose 4 percent to $5.85 in pre-market trading after dropping 54.67 percent on Thursday.
    ArQule, Inc. (NASDAQ: ARQL) rose 3.8 percent to $4.70 in pre-market trading after gaining 4.86 percent on Thursday.
    Babcock & Wilcox Enterprises, Inc. (NYSE: BW) shares rose 2.9 percent to $2.85 in pre-market trading after climbing 7.78 percent on Thursday.
    Bilibili Inc. (NASDAQ: BILI) shares rose 2.5 percent to $14.20 in pre-market trading after surging 11.33 percent on Thursday.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

  • [By Maxx Chatsko]

    Shares of development-stage biopharma ArQule (NASDAQ:ARQL) rose nearly 17% today after the company announced two appointments to its management team in two newly created positions. Dr. Marc Schegerin will serve as senior vice president, corporate strategy, communication, and finance. Dr. Shirish Hirani will serve as senior vice president, program management and product planning. 

  • [By Stephan Byrd]

    ArQule, Inc. (NASDAQ:ARQL) Director Ronald M. Lindsay acquired 23,900 shares of the company’s stock in a transaction on Thursday, May 10th. The stock was acquired at an average price of $2.67 per share, for a total transaction of $63,813.00. Following the purchase, the director now directly owns 43,900 shares of the company’s stock, valued at $117,213. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

  • [By Joseph Griffin]

    ArQule (NASDAQ:ARQL)‘s stock had its “buy” rating restated by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. They currently have a $6.00 price target on the biotechnology company’s stock, up from their prior price target of $5.00. Needham & Company LLC’s price target suggests a potential upside of 134.38% from the company’s previous close.

  • [By Logan Wallace]

    ValuEngine downgraded shares of ArQule (NASDAQ:ARQL) from a strong-buy rating to a buy rating in a research report sent to investors on Saturday.

    Several other brokerages also recently issued reports on ARQL. Zacks Investment Research upgraded shares of ArQule from a hold rating to a buy rating and set a $2.75 target price for the company in a research note on Tuesday, May 8th. B. Riley set a $4.00 target price on shares of ArQule and gave the company a buy rating in a research note on Monday, March 26th. Roth Capital raised their target price on shares of ArQule from $5.00 to $6.00 and gave the company a buy rating in a research note on Tuesday, April 17th. BidaskClub upgraded shares of ArQule from a hold rating to a buy rating in a research note on Saturday, May 19th. Finally, Leerink Swann upgraded shares of ArQule from a market perform rating to an outperform rating in a research note on Thursday, April 5th. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating to the company. The company has an average rating of Buy and a consensus price target of $5.35.

Top 10 Biotech Stocks To Invest In 2019: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Jim Crumly]

    Commercial success for Tegsedi is not a done deal even if it’s approved worldwide; Alnylam Pharmaceuticals’ (NASDAQ:ALNY) competing drug patisiran was approved by the FDA on Aug. 10. Alnylam’s clinical testing showed cardiac benefits for patients whose cardiovascular systems have been affected by the disease, and Alnylam believes that will give patisiran an advantage over Tegsedi. But in the conference call, Akcea executives brushed off that concern and pointed to the advantage Tegsedi has in being an injection that can be delivered at home, versus patisiran, which is administered intravenously in a clinic. We shall see.

  • [By Keith Speights]

    It’s not exactly David vs. Goliath. However, Bellicum Pharmaceuticals (NASDAQ:BLCM) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are definitely in different leagues right now. Both are clinical-stage biotechs, but Bellicum’s market cap is less than $350 million while Alnylam’s market cap is close to $10 billion.

  • [By Motley Fool Transcription]

    Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Q4 2019 Earnings Conference CallFeb. 7, 2017, 4:30 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Brian Orelli]

    The delay in an FDA decision for Tegsedi puts it behind competitor Alnylam Pharmaceuticals (NASDAQ:ALNY), which expects to hear from the FDA by Aug. 11 for its hATTR drug patisiran. But Sarah Boyce, the president at Akcea Therapeutics, doesn’t think a few months will really matter: “We don’t really feel that’s going to have any impact and the drugs will be close enough together from a launch perspective. So not really [going] to make any adjustments, and we’re very well prepared to be ready to launch following approval.”

Hot Biotech Stocks To Invest In 2019

Conatus Pharmaceuticals (NASDAQ:CNAT) had its price objective reduced by HC Wainwright from $14.00 to $8.00 in a report published on Monday, The Fly reports. They currently have a buy rating on the biotechnology company’s stock.

Several other equities research analysts have also issued reports on the company. Zacks Investment Research lowered Conatus Pharmaceuticals from a hold rating to a sell rating in a report on Monday, March 4th. Roth Capital reiterated a buy rating on shares of Conatus Pharmaceuticals in a report on Wednesday, February 13th. ValuEngine upgraded Conatus Pharmaceuticals from a sell rating to a hold rating in a report on Wednesday, January 2nd. SunTrust Banks reduced their target price on Conatus Pharmaceuticals to $12.00 and set a buy rating for the company in a report on Thursday, December 6th. Finally, Stifel Nicolaus lowered Conatus Pharmaceuticals from a buy rating to a hold rating and set a $4.00 target price for the company. in a report on Thursday, December 6th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. Conatus Pharmaceuticals presently has a consensus rating of Hold and an average price target of $7.10.

Hot Biotech Stocks To Invest In 2019: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Joseph Griffin]

    ArQule (NASDAQ:ARQL)‘s stock had its “buy” rating restated by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. They currently have a $6.00 price target on the biotechnology company’s stock, up from their prior price target of $5.00. Needham & Company LLC’s price target suggests a potential upside of 134.38% from the company’s previous close.

  • [By Logan Wallace]

    ValuEngine downgraded shares of ArQule (NASDAQ:ARQL) from a strong-buy rating to a buy rating in a research report sent to investors on Saturday.

    Several other brokerages also recently issued reports on ARQL. Zacks Investment Research upgraded shares of ArQule from a hold rating to a buy rating and set a $2.75 target price for the company in a research note on Tuesday, May 8th. B. Riley set a $4.00 target price on shares of ArQule and gave the company a buy rating in a research note on Monday, March 26th. Roth Capital raised their target price on shares of ArQule from $5.00 to $6.00 and gave the company a buy rating in a research note on Tuesday, April 17th. BidaskClub upgraded shares of ArQule from a hold rating to a buy rating in a research note on Saturday, May 19th. Finally, Leerink Swann upgraded shares of ArQule from a market perform rating to an outperform rating in a research note on Thursday, April 5th. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating to the company. The company has an average rating of Buy and a consensus price target of $5.35.

  • [By Ethan Ryder]

    ArQule, Inc. (NASDAQ:ARQL) insider Value Fund L. P. Biotechnology sold 1,035,939 shares of the business’s stock in a transaction dated Wednesday, May 30th. The shares were sold at an average price of $5.00, for a total value of $5,179,695.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

  • [By Money Morning Staff Reports]

    But Blink and our other penny stocks to watch are unlikely to continue to lock in such spectacular gains in June. After looking at our 10 top penny stocks to watch this month, we’ll show you a small-cap stock with great profit potential in its future…

    Penny Stock Current Share Price Law Month’s Gain
     Blink Charging Co. (Nasdaq: BLNK) $7.07 439.85%
    Senes Tech Inc. (Nasdaq: SNES) $1.27 175.40%
    Vivis Inc. (Nasdaq: VVUS) $0.77 150.41%
    Adomani Inc. (Nasdaq: ADOM) $1.49 137.68%
    NF Energy Saving Co. (Nasdaq: NFEC) $2.34 134.88%
    Vaalco Energy Inc. (NYSE: EGY) $2.15 109.06%
    Heat Biologics Inc. (Nasdaq: HTBX) $2.35 99.12%
    ArQule Inc. (Nasdaq: ARQL) $4.88 90.74%
    LiqTech International Inc. (NYSE: LIQT) $0.66 85.60%
    Transenterix Inc. (NYSE: TRXC) $3.46 77.84%

    While last month’s gains are tremendous, they also illustrate the inherent dangers that come with investing in penny stocks.

Hot Biotech Stocks To Invest In 2019: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Cory Renauer]

    Anyone who likes a good underdog story will want to keep their eye on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) and GW Pharmaceuticals PLC (NASDAQ:GWPH) through this year and next as they launch their first products in the U.S. Smaller biotechs have a terrible track record when it comes to launching new drugs on their own, but most analysts expect these companies to buck the trend and propel their recently approved drugs to blockbuster status within a few years.

  • [By Max Byerly]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($1.41) EPS for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.06. The business had revenue of $21.90 million during the quarter, compared to analysts’ expectations of $35.23 million. Alnylam Pharmaceuticals had a negative return on equity of 36.81% and a negative net margin of 565.20%. The business’s quarterly revenue was up 15.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.25) earnings per share. equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -6.7 earnings per share for the current fiscal year.

  • [By Keith Speights]

    Speaking of competition, Ionis should have its hands full battling rivals for Tegsedi assuming the drug wins approval. Alnylam (NASDAQ:ALNY) anticipates winning FDA approval for its hATTR drug patisiran within a few weeks. Because the FDA delayed its decision on Tegsedi, Alnylam appears to be in position to reach the market first. In addition to its first-mover advantage, patisiran appears to have an edge over Tegsedi in efficacy and safety based on clinical data for the two drugs. 

  • [By Shane Hupp]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by equities research analysts at Morgan Stanley from $107.00 to $99.00 in a report released on Friday. The firm presently has an “equal weight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price objective would indicate a potential upside of 3.97% from the stock’s current price.

Hot Biotech Stocks To Invest In 2019: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Dan Caplinger]

    The iShares biotech ETF has a structure that’s familiar to anyone who invests regularly in exchange-traded funds. The ETF tracks an index of nearly 200 biotech and pharmaceutical stocks, with roughly 80% of assets dedicated to true biotechs and the rest split evenly between pharma and life sciences equipment and services providers. Top ETF holdings Biogen (NASDAQ:BIIB), Amgen (NASDAQ:AMGN), and Gilead Sciences (NASDAQ:GILD) make up a total of roughly 25% of the fund’s assets.

  • [By Shane Hupp]

    Investors sold shares of Amgen, Inc. (NASDAQ:AMGN) on strength during trading hours on Thursday. $63.15 million flowed into the stock on the tick-up and $134.51 million flowed out of the stock on the tick-down, for a money net flow of $71.36 million out of the stock. Of all stocks tracked, Amgen had the 0th highest net out-flow for the day. Amgen traded up $2.11 for the day and closed at $185.79

  • [By Joseph Griffin]

    In other news, SVP Cynthia M. Patton sold 1,777 shares of the business’s stock in a transaction that occurred on Thursday, November 29th. The stock was sold at an average price of $202.88, for a total transaction of $360,517.76. Following the completion of the transaction, the senior vice president now directly owns 23,090 shares in the company, valued at $4,684,499.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Tyler Jacks sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, December 6th. The stock was sold at an average price of $195.41, for a total value of $3,908,200.00. Following the transaction, the director now owns 28,979 shares of the company’s stock, valued at $5,662,786.39. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 23,777 shares of company stock valued at $4,648,718. Insiders own 0.27% of the company’s stock.

    COPYRIGHT VIOLATION WARNING: “Boston Financial Mangement LLC Has $3.86 Million Stake in Amgen, Inc. (AMGN)” was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. and international copyright law. The legal version of this article can be viewed at www.tickerreport.com/banking-finance/4162787/boston-financial-mangement-llc-has-3-86-million-stake-in-amgen-inc-amgn.html.

    Amgen Profile

  • [By Keith Speights]

    Gilead Sciences (NASDAQ:GILD), Amgen (NASDAQ:AMGN), and Johnson & Johnson (NYSE:JNJ) rank as the three top biopharmaceutical companies when it comes to cash stockpiles. Here’s what these drugmakers are most likely to do with all that money — and whether or not you should consider investing some of your hard-earned cash to buy their stocks.

  • [By Logan Wallace]

    Eqis Capital Management Inc. grew its position in Amgen, Inc. (NASDAQ:AMGN) by 3.3% in the second quarter, according to its most recent filing with the SEC. The fund owned 42,769 shares of the medical research company’s stock after acquiring an additional 1,361 shares during the period. Amgen accounts for approximately 0.5% of Eqis Capital Management Inc.’s investment portfolio, making the stock its 23rd biggest position. Eqis Capital Management Inc.’s holdings in Amgen were worth $7,895,000 at the end of the most recent reporting period.

  • [By Keith Speights]

    Amgen (NASDAQ:AMGN) ranks No. 1 among all biotech stocks when it comes to market cap. It’s one of the most profitable biotechs and claims one of the largest cash stockpiles in the industry.

Hot Biotech Stocks To Invest In 2019: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By ]

    What should investors do with shares of Celgene (CELG) , Biogen Idec (BIIB) , Gilead Science (GILD) and Regeneron (REGN) ? Cramer once proclaimed these high-fliers his “four horsemen of biotech,” but lately they’ve lost all of their traction, with Celgene down 21%, Biogen off 14%, Gilead down 9% and Regeneron off 23% so far this year.

  • [By Jim Crumly]

    As for individual stocks, Biogen (NASDAQ:BIIB) announced it’s buying Nightstar Therapeutics (NASDAQ:NITE), and Village Farms International (NASDAQ:VFF) is launching an effort to enter the U.S. hemp market.

  • [By Brian Orelli]

    Shares of Ionis Pharmaceuticals (NASDAQ:IONS) ended the day down 10.6% after an earnings report from partner Biogen (NASDAQ:BIIB) started the day on a sour note. Then shares dropped even further midday after data was released for IONIS-HTTRx, a treatment for Huntington’s disease. Biogen managed to end the day in the green, up 1.1%.

  • [By Joseph Griffin]

    Rhenman & Partners Asset Management AB lifted its holdings in shares of Biogen Inc (NASDAQ:BIIB) by 130.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 30,000 shares of the biotechnology company’s stock after purchasing an additional 17,000 shares during the quarter. Rhenman & Partners Asset Management AB’s holdings in Biogen were worth $10,599,000 as of its most recent filing with the Securities and Exchange Commission.

  • [By Keith Speights]

    Surprising only begins to describe the latest clinical study results announced by Biogen (NASDAQ:BIIB) and its partner, Japanese drugmaker Eisai (NASDAQOTH:ESALY). On July 5, the two companies reported positive topline results from a phase 2 clinical study of experimental Alzheimer’s disease drug BAN2401 at 18 months.

Top Biotech Stocks To Own Right Now

Biotech stocks are known for dramatic gains, and this year’s top performers are helping the industry live up to its reputation. Investors excited about the future of gene therapy have seen CRISPR Therapeutics AG (NASDAQ:CRSP) more than quadruple its shareholders’ money over the past year.

The gene-editing stock has put up a dazzling performance, but it pales in comparison to Endocyte Inc. (NASDAQ:MRNS) and Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR), which have absolutely exploded lately. Let’s look at what’s next for these high-flying biotech stocks to see if any have a shot at climbing further.

Image source: Getty Images.

1. Endocyte Inc.: Waiting for a Vision 

Shares of this precommercial biotech have risen a spectacular 807% over the past year as investors become increasingly confident about its new lead candidate’s chances. The radioactive cancer treatment called Lu-PSMA-617 recently began a pivotal trial called Vision that will test its ability to increase overall survival for prostate cancer patients that have run out of treatment options.

Top Biotech Stocks To Own Right Now: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By Cory Renauer]

    Healthcare is something that people need no matter what’s happening in the economy, so the sector is full of great stocks for investors seeking steadily growing income streams. That said, Abiomed, Inc. (NASDAQ:ABMD), Biogen Inc. (NASDAQ:BIIB), and Canopy Growth Corporation (NYSE:CGC) are three popular healthcare stocks that would make horrible additions to a retirement portfolio.

  • [By Todd Campbell]

    Unfortunately for investors, June’s discovery wasn’t exciting enough for Sangamo partners Biogen (NASDAQ:BIIB) and Shire (NASDAQ:SHPG). In 2015, Biogen announced a delay to its beta-thalassemia and sickle-cell disease treatment program with Sangamo. And then Shire, a Sangamo collaboration partner since 2012, walked away from Sangamo’s hemophilia program.

  • [By Brian Orelli]

    Data source: Ionis Pharmaceuticals.

    What happened with Ionis Pharmaceuticals this quarter?
    Royalties from Biogen (NASDAQ:BIIB) for sales of Spinraza came in at $57 million, more than double the year-ago quarter. The rest of the revenue comes from research and development revenue, which can vary from quarter to quarter due to milestone payments. In July, Ionis’ marketing partner Akcea Therapeutics (NASDAQ:AKCA) received EU approval for Tegsedi, the brand name for inotersen that treats hereditary transthyretin amyloidosis (ATTR). Earlier this month, Akcea licensed the Latin American rights to Tegsedi and Waylivra, which treats diseases with high lipid levels, to PTC Therapeutics (NASDAQ:PTCT); Ionis gets 60% of the milestone and royalty payments from PTC Therapeutics for Tegsedi and 50% of the payments for Waylivra. The larger loss came from an increase in R&D expenses, as Ionis and Akcea — which is still included in Ionis’ profit-loss statement because Ionis owns a majority stake — continue to advance Ionis’ pipeline. Selling, general, and administrative costs also increased as Akcea prepares to launch Tegsedi and Waylivra. Ionis’ balance sheet can certainly absorb the quarterly loss; the biotech ended the quarter with $2 billion in the bank thanks to its latest deal with Biogen, which is plenty to get by as it waits for revenue to start rolling in.

    Image source: Getty Images.

  • [By Brian Orelli]

    Data source: Ionis Pharmaceuticals.

    What happened with Ionis Pharmaceuticals this quarter?
    Revenue increased thanks to $41 million in royalties from Biogen’s (NASDAQ:BIIB) sales of Spinraza, up from just $5 million in the year-ago quarter. Because the tiered royalty rates reset each year, the royalties as a percentage of sales will end up being higher in the quarters to come this year. Despite the higher revenue, earnings turned negative on a GAAP (generally accepted accounting principles) basis: Ionis and Akcea Therapeutics (NASDAQ:AKCA) increased spending in preparation for the launch of Tegsedi for hereditary transthyretin amyloidosis (hATTR), and Waylivra for familial chylomicronemia syndrome, a rare disease that causes the buildup of lipids. Ionis is still the majority owner of Akcea, so its financials are incorporated into Ionis’ financials. The Food and Drug Administration pushed back its goal for making a decision on the marketing application for Tegsedi (the new brand name for inotersen) to Oct. 6, 2018. Ionis provided additional data analysis that the FDA needs additional time to review. In April, Ionis signed another deal with Biogen to develop antisense drugs for neurological disorders. In the deal, Ionis gets $1 billion up front, including an equity investment, in exchange for Biogen having first choice of neurology targets on which to exclusively collaborate with Ionis. Biogen is paying for everything beyond the initial discovery stage, with Ionis eligible for royalties and milestone payments as the drugs advance.

    Image source: Getty Images.

Top Biotech Stocks To Own Right Now: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Shares of ArQule, Inc. (NASDAQ:ARQL) were down 5.4% during trading on Wednesday . The company traded as low as $4.71 and last traded at $4.73. Approximately 3,358,864 shares traded hands during trading, an increase of 289% from the average daily volume of 863,008 shares. The stock had previously closed at $5.00.

  • [By Logan Wallace]

    ValuEngine downgraded shares of ArQule (NASDAQ:ARQL) from a strong-buy rating to a buy rating in a research report sent to investors on Saturday.

    Several other brokerages also recently issued reports on ARQL. Zacks Investment Research upgraded shares of ArQule from a hold rating to a buy rating and set a $2.75 target price for the company in a research note on Tuesday, May 8th. B. Riley set a $4.00 target price on shares of ArQule and gave the company a buy rating in a research note on Monday, March 26th. Roth Capital raised their target price on shares of ArQule from $5.00 to $6.00 and gave the company a buy rating in a research note on Tuesday, April 17th. BidaskClub upgraded shares of ArQule from a hold rating to a buy rating in a research note on Saturday, May 19th. Finally, Leerink Swann upgraded shares of ArQule from a market perform rating to an outperform rating in a research note on Thursday, April 5th. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating to the company. The company has an average rating of Buy and a consensus price target of $5.35.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on ArQule (ARQL)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    ArQule, Inc. (NASDAQ:ARQL) insider Value Fund L. P. Biotechnology sold 1,035,939 shares of the business’s stock in a transaction dated Wednesday, May 30th. The shares were sold at an average price of $5.00, for a total value of $5,179,695.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Top Biotech Stocks To Own Right Now: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Joseph Griffin]

    South Dakota Investment Council lowered its stake in Amgen (NASDAQ:AMGN) by 59.4% during the 1st quarter, HoldingsChannel reports. The fund owned 77,041 shares of the medical research company’s stock after selling 112,589 shares during the quarter. South Dakota Investment Council’s holdings in Amgen were worth $13,134,000 at the end of the most recent quarter.

  • [By Stephan Byrd]

    Private Capital Group LLC boosted its stake in Amgen, Inc. (NASDAQ:AMGN) by 1,703.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,362 shares of the medical research company’s stock after purchasing an additional 2,231 shares during the period. Private Capital Group LLC’s holdings in Amgen were worth $403,000 at the end of the most recent reporting period.

  • [By Ethan Ryder]

    Wayne Hummer Investments L.L.C. trimmed its position in shares of Amgen (NASDAQ:AMGN) by 11.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,311 shares of the medical research company’s stock after selling 303 shares during the period. Wayne Hummer Investments L.L.C.’s holdings in Amgen were worth $394,000 at the end of the most recent quarter.

Top Biotech Stocks To Own Right Now: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Cory Renauer]

    Anyone who likes a good underdog story will want to keep their eye on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) and GW Pharmaceuticals PLC (NASDAQ:GWPH) through this year and next as they launch their first products in the U.S. Smaller biotechs have a terrible track record when it comes to launching new drugs on their own, but most analysts expect these companies to buck the trend and propel their recently approved drugs to blockbuster status within a few years.

  • [By Brian Orelli]

    Earlier this week, Dicerna released promising interim phase I data for its lead drug, DCR-PHXC, in patients with primary hyperoxaluria type 1 and type 2. The company plans to start a trial to be used to support an FDA approval in the first quarter of 2019, but that’ll put it behind Alnylam Pharmaceuticals (NASDAQ:ALNY), which is about to start a phase 3 study testing its drug, lumasiran, in patients with primary hyperoxaluria type 1. Hopefully, Dicerna can use some of its new capital to help accelerate enrollment in its trial to try to catch up to Alnylam.

  • [By Brian Orelli]

    Following the Food and Drug Administration (FDA) approval of Onpattro, Alnylam Pharmaceuticals’ (NASDAQ:ALNY) first drug to treat hereditary transthyretin-mediated amyloidosis (hATTR), the biotech held a conference call to go over the plan for launch. Here are three things management wants investors to know:

  • [By Jim Crumly]

    Commercial success for Tegsedi is not a done deal even if it’s approved worldwide; Alnylam Pharmaceuticals’ (NASDAQ:ALNY) competing drug patisiran was approved by the FDA on Aug. 10. Alnylam’s clinical testing showed cardiac benefits for patients whose cardiovascular systems have been affected by the disease, and Alnylam believes that will give patisiran an advantage over Tegsedi. But in the conference call, Akcea executives brushed off that concern and pointed to the advantage Tegsedi has in being an injection that can be delivered at home, versus patisiran, which is administered intravenously in a clinic. We shall see.

Top 10 Heal Care Stocks To Invest In Right Now

Durect Corp (NASDAQ:DRRX) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Durect Corp is a biopharmaceutical company. It develops pharmaceutical products based on two categories which include new chemical entities and drug delivery programs. The lead candidate for the company is DUR-928. Durect Corp has a market cap of $111.820 million; its shares were traded at around $0.69 with and P/S ratio of 3.11.

For the last quarter Durect Corp reported a revenue of $8.04 million, compared with the revenue of $20.75 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $18.6 million, a decrease of 62.2% from the previous year. For the last five years Durect Corp had an average revenue growth rate of 10.3% a year.

The reported loss per diluted share was 16 cents for the year, compared with the loss per share of $0.19 in the previous year. The Durect Corp had an operating margin of -127.23%, compared with the operating margin of -4.55% a year before. The 10-year historical median operating margin of Durect Corp is -108.14%. The profitability rank of the company is 2 (out of 10).

Top 10 Heal Care Stocks To Invest In Right Now: Midstates Petroleum Company, Inc.(MPO)

Advisors’ Opinion:

  • [By Shane Hupp]

    These are some of the news articles that may have effected Accern’s analysis:

    Get Midstates Petroleum alerts:

    Centerbridge Credit Partners M Sells 109,893 Shares of Midstates Petroleum (MPO) Stock (americanbankingnews.com) Midstates Petroleum (MPO) Major Shareholder Centerbridge Credit Partners M Sells 171,200 Shares (americanbankingnews.com) Midstates Petroleum (MPO) CAO Richard Wayne Mccullough Sells 3,170 Shares (americanbankingnews.com) Midstates Petroleum (MPO) Director Michael Reddin Purchases 10,100 Shares (americanbankingnews.com) Midstates Petroleum (MPO) CEO David J. Sambrooks Acquires 15,300 Shares (americanbankingnews.com)

    A number of research firms recently commented on MPO. TheStreet downgraded shares of Midstates Petroleum from a “c-” rating to a “d” rating in a research report on Wednesday, March 14th. ValuEngine downgraded shares of Midstates Petroleum from a “hold” rating to a “sell” rating in a research report on Thursday, March 1st.

  • [By Ethan Ryder]

    News stories about Midstates Petroleum (NYSE:MPO) have been trending somewhat positive on Tuesday, Accern reports. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Midstates Petroleum earned a news impact score of 0.25 on Accern’s scale. Accern also assigned headlines about the energy producer an impact score of 45.5617713297556 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

  • [By Shane Hupp]

    Bailard Inc. bought a new stake in Midstates Petroleum Company Inc (NYSE:MPO) in the 4th quarter, HoldingsChannel reports. The firm bought 46,400 shares of the energy producer’s stock, valued at approximately $348,000.

  • [By Stephan Byrd]

    Press coverage about Midstates Petroleum (NYSE:MPO) has trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Midstates Petroleum earned a daily sentiment score of 0.03 on Accern’s scale. Accern also assigned news headlines about the energy producer an impact score of 46.005644497441 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

  • [By Stephan Byrd]

    Midstates Petroleum Company Inc (NYSE:MPO) shares hit a new 52-week low during trading on Tuesday . The company traded as low as $11.23 and last traded at $11.31, with a volume of 1700 shares trading hands. The stock had previously closed at $11.63.

Top 10 Heal Care Stocks To Invest In Right Now: Macy's Inc(M)

Advisors’ Opinion:

  • [By Motley Fool Staff]

    In this segment from MarketFoolery, host Chris Hill and senior analyst Matt Argersinger discuss the totally solid performance that department store chain Macy’s (NYSE:M) turned in for its second quarter. Despite decent results, the stock dropped by a double-digit percentage.

  • [By Chris Lange]

    Macy’s Inc. (NYSE: M) will share its most recent quarterly earnings on Tuesday. The consensus estimates call for $2.68 in earnings per share (EPS) on $8.65 billion in revenue. Shares ended the week at $26.74, in a 52-week trading range of $17.41 to $33.73. The consensus price target is $26.69.

  • [By Max Byerly]

    Community Bank & Trust Waco Texas decreased its holdings in shares of Macy’s Inc (NYSE:M) by 17.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,504 shares of the company’s stock after selling 1,533 shares during the period. Community Bank & Trust Waco Texas’ holdings in Macy’s were worth $261,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

  • [By Rich Duprey]

    Below is a mix of all of these types of companies. The stocks under my magnifying glass are Facebook (NASDAQ:FB), Macy’s (NYSE:M), and Gaming & Leisure Properties (NASDAQ:GLPI). Read on to see what’s wrong with two of these companies, and why the third one is a superior business.

Top 10 Heal Care Stocks To Invest In Right Now: Empire Resorts Inc.(NYNY)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Wendys (NASDAQ: WEN) and Empire Resorts (NASDAQ:NYNY) are both retail/wholesale companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

  • [By Max Byerly]

    Simplicity Esports and Gaming (NASDAQ:WINR) and Empire Resorts (NASDAQ:NYNY) are both small-cap consumer discretionary companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership.

Top 10 Heal Care Stocks To Invest In Right Now: Movado Group Inc.(MOV)

Advisors’ Opinion:

  • [By Lisa Levin] Companies Reporting Before The Bell
    Dick's Sporting Goods, Inc. (NYSE: DKS) is projected to report its quarterly earnings at $0.45 per share on revenue of $1.89 billion.
    Columbus McKinnon Corporation (NASDAQ: CMCO) is estimated to report its quarterly earnings at $0.5 per share on revenue of $209.35 million.
    Analog Devices, Inc. (NASDAQ: ADI) is expected to report its quarterly earnings at $1.38 per share on revenue of $1.47 billion.
    Michael Kors Holdings Limited (NYSE: KORS) is projected to report its quarterly earnings at $0.59 per share on revenue of $1.15 billion.
    Movado Group, Inc. (NYSE: MOV) is expected to report its quarterly earnings at $0.11 per share on revenue of $109.47 million.
    Chico's FAS, Inc. (NYSE: CHS) is estimated to report its quarterly earnings at $0.26 per share on revenue of $552.31 million.
    DSW Inc. (NYSE: DSW) is projected to report its quarterly earnings at $0.37 per share on revenue of $681.89 million.
    Daktronics, Inc. (NASDAQ: DAKT) is expected to report its quarterly earnings at $0.05 per share on revenue of $147.20 million.
    Destination XL Group, Inc. (NASDAQ: DXLG) is estimated to report a quarterly loss at $0.14 per share on revenue of $107.63 million.
    Bank of Montreal (NYSE: BMO) is expected to report its quarterly earnings at $1.67 per share on revenue of $4.21 billion.
    MakeMyTrip Limited (NASDAQ: MMYT) is projected to report its quarterly loss at $0.39 per share on revenue of $143.03 million.
    EVINE Live Inc. (NASDAQ: EVLV) is expected to report its quarterly loss at $0.02 per share on revenue of $155.98 million.
    RBC Bearings Incorporated (NASDAQ: ROLL) is estimated to report its quarterly earnings at $1.14 per share on revenue of $175.55 million.

     

  • [By Dan Caplinger]

    Wall Street had another summer celebration on Wednesday, as the S&P 500 and Nasdaq Composite once again set records. Most investors attributed the gains to a 4.2% rise in gross domestic product during the second quarter, which was slightly faster than the initial estimate on GDP had suggested last month. Yet even with a favorable attitude prevailing throughout most of the market, some stocks suffered setbacks. Movado Group (NYSE:MOV), Roku (NASDAQ:ROKU), and American Eagle Outfitters (NYSE:AEO) were among the worst performers on the day. Here’s why they did so poorly.

  • [By Ethan Ryder]

    Strs Ohio decreased its holdings in shares of Movado Group, Inc (NYSE:MOV) by 24.1% in the 2nd quarter, HoldingsChannel reports. The fund owned 18,000 shares of the company’s stock after selling 5,700 shares during the period. Strs Ohio’s holdings in Movado Group were worth $869,000 at the end of the most recent reporting period.

  • [By Logan Wallace]

    Shares of Movado Group, Inc (NYSE:MOV) have earned a consensus rating of “Hold” from the six ratings firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation, one has given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $39.00.

Top 10 Heal Care Stocks To Invest In Right Now: First Connecticut Bancorp, Inc.(FBNK)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on First Connecticut Bancorp (FBNK)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    First Connecticut Bancorp (NASDAQ: FBNK) and Entegra Financial (NASDAQ:ENFC) are both small-cap finance companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, analyst recommendations, institutional ownership and risk.

  • [By Max Byerly]

    BidaskClub downgraded shares of First Connecticut Bancorp (NASDAQ:FBNK) from a hold rating to a sell rating in a research note issued to investors on Wednesday morning.

  • [By Shane Hupp]

    Wells Fargo & Company MN boosted its holdings in shares of First Connecticut Bancorp Inc (NASDAQ:FBNK) by 8.6% in the first quarter, Holdings Channel reports. The institutional investor owned 148,333 shares of the bank’s stock after purchasing an additional 11,719 shares during the quarter. Wells Fargo & Company MN’s holdings in First Connecticut Bancorp were worth $3,798,000 as of its most recent filing with the Securities and Exchange Commission.

Top 10 Heal Care Stocks To Invest In Right Now: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Joseph Griffin]

    BidaskClub lowered shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a strong-buy rating to a buy rating in a research report released on Monday.

  • [By Joseph Griffin]

    Northern Trust Corp lifted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 4.4% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 492,768 shares of the biopharmaceutical company’s stock after purchasing an additional 20,992 shares during the period. Northern Trust Corp owned about 0.49% of Alnylam Pharmaceuticals worth $48,533,000 at the end of the most recent quarter.

  • [By Brian Orelli]

    Following the Food and Drug Administration (FDA) approval of Onpattro, Alnylam Pharmaceuticals’ (NASDAQ:ALNY) first drug to treat hereditary transthyretin-mediated amyloidosis (hATTR), the biotech held a conference call to go over the plan for launch. Here are three things management wants investors to know:

  • [By Cory Renauer]

    After 16 years as a public company, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) finally got the go-ahead to launch its first product earlier this month. Onpattro is the first in a new class of drugs that alter gene expression, but Pfizer, Inc. (NYSE:PFE) just reported some impressive results with a possible competitor that works a lot differently.

  • [By Brian Orelli]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) and Ionis Pharmaceuticals (NASDAQ:IONS) looked to be in a two-horse race to develop TTR amyloidosis (ATTR) drugs. Alnylam recently got its drug Onpattro approved, while Ionis Pharmaceuticals and its marketing partner Akcea Therapeutics (NASDAQ:AKCA) should hear about Tegsedi by Oct. 6. Tegsedi was approved in the EU last month.

Top 10 Heal Care Stocks To Invest In Right Now: Nuveen Energy MLP Total Return Fund(JMF)

Advisors’ Opinion:

  • [By Joseph Griffin]

    JPMorgan Mid Cap Investment Trust PLC (LON:JMF) announced a dividend on Thursday, September 27th, Upcoming.Co.Uk reports. Investors of record on Thursday, October 11th will be given a dividend of GBX 20 ($0.26) per share on Thursday, November 15th. This represents a yield of 1.69%. The ex-dividend date of this dividend is Thursday, October 11th. This is a boost from JPMorgan Mid Cap Investment Trust’s previous dividend of $8.00. The official announcement can be seen at this link.

Top 10 Heal Care Stocks To Invest In Right Now: John Hancock Tax-Advantaged Global Shareholder Yield Fund(HTY)

Advisors’ Opinion:

  • [By Shane Hupp]

    John Hancock Tax-Advntgd Glbl SH Yld Fd (NYSE:HTY) declared a quarterly dividend on Thursday, August 23rd, Wall Street Journal reports. Shareholders of record on Friday, September 14th will be paid a dividend of 0.16 per share on Friday, September 28th. This represents a $0.64 annualized dividend and a yield of 7.68%. The ex-dividend date is Thursday, September 13th.

Top 10 Heal Care Stocks To Invest In Right Now: Flushing Financial Corporation(FFIC)

Advisors’ Opinion:

  • [By Shane Hupp]

    BidaskClub downgraded shares of Flushing Financial (NASDAQ:FFIC) from a sell rating to a strong sell rating in a research note published on Saturday.

  • [By Joseph Griffin]

    BidaskClub downgraded shares of Flushing Financial (NASDAQ:FFIC) from a sell rating to a strong sell rating in a research report released on Wednesday.

  • [By Max Byerly]

    BidaskClub cut shares of Flushing Financial (NASDAQ:FFIC) from a hold rating to a sell rating in a research report report published on Monday morning.

  • [By Shane Hupp]

    Flushing Financial (NASDAQ:FFIC) was upgraded by equities research analysts at ValuEngine from a “sell” rating to a “hold” rating in a note issued to investors on Friday.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Flushing Financial (FFIC)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Heal Care Stocks To Invest In Right Now: Clarke(t)

Advisors’ Opinion:

  • [By Daniel Sparks]

    With AT&T (NYSE:T) closing its acquisition of media giant Time Warner last week, investors will be watching to see how well the telecom company can integrate Time Warner’s powerful content assets, including Warner Bros., HBO, CNN, TNT, and TBS, into its business. In theory, AT&T’s acquisition looks great. “Combine [these content assets] with AT&T’s strengths in direct-to-consumer distribution, and we offer customers a differentiated, high-quality, mobile-first entertainment experience,” explained AT&T CEO Randall Stephenson. But will it be as easy as it sounds?

  • [By Jon C. Ogg]

    AT&T Inc. (NYSE: T) may have won a victory after the approval of its Time Warner acquisition was finally cleared by U.S. regulators. Whether that victory was truly good depends on whom you ask, and it may be years before investors get to find out whether marrying a major telecom platform with a media and content creator will work in the new world of converged media. One key analyst on Wall Street believes the deal will not hurt shareholders further, and he has effectively called a bottom in the stock.

  • [By Shane Hupp]

    TELUS Co. (NYSE:TU) (TSE:T) – Research analysts at National Bank Financial issued their Q2 2018 earnings estimates for TELUS in a research report issued to clients and investors on Tuesday, July 10th. National Bank Financial analyst A. Shine anticipates that the Wireless communications provider will post earnings of $0.54 per share for the quarter.

  • [By Paul Ausick]

    AT&T
    AT&T Inc. (NYSE: T) inched back up to its accustomed spot as the No. 1  most shorted NYSE stock. Short interest rose by 0.7% to just over 195.3 million, some 3.2% of the stock’s total float. As of the end of this month, it would take seven days to cover all short positions. The stock ended trading on Monday with a price of $34.18 a share, within a 52-week range of $31.17 to $39.80.

Top 5 Biotech Stocks To Own For 2019

CytomX Therapeutics Inc (NASDAQ:CTMX) – Stock analysts at Jefferies Financial Group issued their Q3 2018 EPS estimates for shares of CytomX Therapeutics in a research report issued on Wednesday, August 8th. Jefferies Financial Group analyst B. Amin expects that the biotechnology company will post earnings per share of ($0.57) for the quarter. Jefferies Financial Group also issued estimates for CytomX Therapeutics’ Q4 2018 earnings at ($0.64) EPS, FY2018 earnings at ($1.98) EPS, FY2019 earnings at ($2.73) EPS, FY2020 earnings at ($3.12) EPS, FY2021 earnings at ($3.27) EPS and FY2022 earnings at ($3.33) EPS.

Get CytomX Therapeutics alerts:

A number of other brokerages have also commented on CTMX. Cantor Fitzgerald set a $40.00 price objective on CytomX Therapeutics and gave the company a “buy” rating in a report on Wednesday, May 16th. ValuEngine raised CytomX Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, June 2nd. SunTrust Banks initiated coverage on CytomX Therapeutics in a report on Friday, June 1st. They set a “buy” rating and a $38.00 price objective on the stock. Cowen reissued a “buy” rating on shares of CytomX Therapeutics in a report on Thursday, May 10th. Finally, Zacks Investment Research raised CytomX Therapeutics from a “hold” rating to a “buy” rating and set a $28.00 price objective on the stock in a report on Tuesday, May 8th. Three investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $38.38.

Top 5 Biotech Stocks To Own For 2019: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By George Budwell]

    The spark? Nightstar’s shares are bolting higher in response to an $877 million buyout offer from biotech heavyweight Biogen (NASDAQ:BIIB). Per the terms of the agreement, Biogen will pay $25.50 in cash for each share of Nightstar, which translates to a hefty 68% premium when compared to where the gene therapy company’s shares closed on Friday. According to the two companies, this transaction should close by midyear.

  • [By Trey Thoelcke]

    Biogen Inc. (NASDAQ: BIIB) also saw a death cross earlier this month, and the gap between the moving averages is now more than 9% of the share price. The stock was just downgraded by one analyst and another recently anticipated no growth in the share price. The stock is up more than 6% since the beginning of the year. The consensus recommendation remains to buy Biogen shares.

  • [By Chris Lange]

    Short interest in Biogen Inc. (NASDAQ: BIIB) increased to 3.50 million shares from the previous 3.16 million. The stock recently traded at $262.15, within a 52-week range of $244.28 to $370.57.

  • [By Todd Campbell]

    Many companies could see share prices pop or drop based on fast-approaching news in these indications, but six companies could be particularly exciting for investors to keep tabs on from here. In this episode of The Motley Fool’s Industry Focus Healthcare, host Shannon Jones is joined by Motley Fool contributor Todd Campbell to discuss:

    The imminent results for Biogen’s (NASDAQ:BIIB) Alzheimer’s disease moonshot; Why European regulators could make this a big year for bluebird bio (NASDAQ:BLUE); How targeting the cause of sickle-cell disease could pan out for Global Blood Therapeutics (NASDAQ:GBT); A new treatment for peanut allergy is around the corner thanks to Aimmune Therapeutics (NASDAQ:AIMT); Vertex Pharmaceuticals’ (NASDAQ:VRTX) big opportunity to significantly boost its addressable market; and The news that could transform Duchenne’s muscular dystrophy treatment and send Sarepta Therapeutics’ (NASDAQ:SRPT) revenue soaring.

    A full transcript follows the video.

Top 5 Biotech Stocks To Own For 2019: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Dan Caplinger]

    Thursday was another down day for the stock market, with new pressure coming from international moves on the macroeconomic front. The European Central Bank signaled that it was ready to provide more accommodative monetary policy, reversing a previous tightening stance and showing its concerns about the prospects for economic growth in the region. Yet favorable earnings reports continued lifting shares of certain individual companies. Rosetta Stone (NYSE:RST), ArQule (NASDAQ:ARQL), and Fly Leasing (NYSE:FLY) were among the top performers. Here’s why they did so well.

  • [By Cory Renauer]

    What’s behind these dramatic gains? Read on to find out.

    Company Gain in H1 2018 Market Cap
    Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) 270% $1.19 billion
    ArQule, Inc. (NASDAQ:ARQL) 235% $482 million
    Endocyte, Inc. (NASDAQ:ECYT) 222% $959 million
    Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) 205% $3.99 billion

    Data source: YCharts.

  • [By Motley Fool Transcribers]

    Arqule Inc  (NASDAQ:ARQL)Q4 2018 Earnings Conference CallMarch 07, 2019, 9:00 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

Top 5 Biotech Stocks To Own For 2019: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Keith Speights]

    It’s a big drugmaker with a blockbuster immunology drug as its top-selling product. It pays an attractive dividend. And it faces some uncertainties. This description fits Amgen (NASDAQ:AMGN), but it applies just as well to Johnson & Johnson (NYSE:JNJ).

  • [By Cory Renauer]

    There’s a lot for investors to like about Amgen Inc. (NASDAQ:AMGN) and Biogen Inc. (NASDAQ:BIIB). Both of these biotech stocks have produced tremendous returns over the past couple of decades, and the businesses they represent still generate enormous profits. 

  • [By Logan Wallace]

    Amgen (NASDAQ:AMGN) was upgraded by stock analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued on Monday.

  • [By Stephan Byrd]

    PNC Financial Services Group Inc. trimmed its stake in Amgen, Inc. (NASDAQ:AMGN) by 0.3% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 2,120,853 shares of the medical research company’s stock after selling 6,484 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Amgen were worth $391,489,000 as of its most recent SEC filing.

Top 5 Biotech Stocks To Own For 2019: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Northern Trust Corp lifted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 4.4% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 492,768 shares of the biopharmaceutical company’s stock after purchasing an additional 20,992 shares during the period. Northern Trust Corp owned about 0.49% of Alnylam Pharmaceuticals worth $48,533,000 at the end of the most recent quarter.

  • [By Cory Renauer]

    After 16 years as a public company, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) finally got the go-ahead to launch its first product earlier this month. Onpattro is the first in a new class of drugs that alter gene expression, but Pfizer, Inc. (NYSE:PFE) just reported some impressive results with a possible competitor that works a lot differently.

  • [By Keith Speights]

    Speaking of competition, Ionis should have its hands full battling rivals for Tegsedi assuming the drug wins approval. Alnylam (NASDAQ:ALNY) anticipates winning FDA approval for its hATTR drug patisiran within a few weeks. Because the FDA delayed its decision on Tegsedi, Alnylam appears to be in position to reach the market first. In addition to its first-mover advantage, patisiran appears to have an edge over Tegsedi in efficacy and safety based on clinical data for the two drugs. 

  • [By Shane Hupp]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by equities research analysts at Morgan Stanley from $107.00 to $99.00 in a report released on Friday. The firm presently has an “equal weight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price objective would indicate a potential upside of 3.97% from the stock’s current price.

  • [By Logan Wallace]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Although Alnylam has a broad and promising pipeline, we note that most candidates are in mid stages of development. These candidates still have a long way to go before hitting the market. The company relies highly on collaborators for funding. Any development/regulatory setback would be a negative for the company.  However, Alnylam reported positive data from the ATLAS study in the first quarter which led to regulatory filings for its late-stage pipeline candidate patisiran and the FDA set an action date of Aug 11, 2018. The company along with its partners Sanofi and The Medicines Company, restarted fitusiran's ATLAS phase III study and advanced inclisiran in the ORION-9, -10, and -11 phase III studies, respectively, with results expected for both programs in 2019. Alnylam expects to achieve the profile of three marketed products by the end of 2020.”